ArticleHeliyon2024
Biogenic silver nanomaterials synthesized from
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Biofabrication of chitosan-loaded gold nanoparticles: investigation of antimicrobial and anticancer activity and its morphological assessment in liver cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Sustainable nanomaterials for precision dental medicine: green synthesis, therapeutic applications, and future directions.Journal of nanobiotechnology · 2026Review
- Integrated metabolomic, nanoformulation, and network pharmacology approach reveals multifunctional bioactivities of anFrontiers in bioengineering and biotechnology · 2026Article
- Homeopathic Medicine: An Intrinsic Nanomaterial for Synthesis of AgNPs for Environmental and Biomedical Applications.ACS omega · 2025Article
- Antibacterial Activity ofJournal of microbiology and biotechnology · 2025Article
- Editorial: Evolution, molecular mechanisms and the strategies to combat antimicrobial resistance (AMR): a One Health approach.Frontiers in cellular and infection microbiology · 2025Article
- Harnessing the Antibacterial, Anti-Diabetic and Anti-Carcinogenic Properties ofPlants (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a surge in antibiotic consumption because of the emergence of resistance among microbial pathogens. In the escalating challenge of antibiotic resistance in microbial pathogens, silver nanoparticles (AgNPs)-mediated therapy has proven to be the most effective and alternative therapeutic strategy for bacterial infections and cancer treatment. This study aims to explore the potential of OsAgNPs derived from
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.